Jose Israel Cruz

Dr. Jose Israel Cruz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2023 in Cells
Verified
Journal Article
Open access
PDF file
Martha GallegosMartha Gallegos
Martha Gallegos
AGAsbiel Felipe Garibaldi-Ríos
Asbiel Felipe Garibaldi-Ríos
JCJose Israel Cruz
Jose Israel Cruz
LVLuis Eduardo Figuera Villanueva
Luis Eduardo Figuera Villanueva
CRCarlos Alberto Ronquillo-Carreón
Carlos Alberto Ronquillo-Carreón
GZGuillermo Zúñiga-González
Guillermo Zúñiga-González
Colorectal cancer (CRC) is a major global health challenge and one of the top 10 cancers in Mexico. Lifestyle and genetic factors influence CRC development, prognosis, and therapeutic response; identifying risk factors, such as the genes involved, is critical to understanding its behavior, mechanisms, and prognosis. The association between KRAS gene variants (rs8720 and rs12587) and CRC in the Mexican population was analyzed. We performed in silico analysis and analyzed 310 healthy individuals and 385 CRC patients using TaqMan assays and real-time PCR. The CC and GG genotypes of rs8720 and rs12587 were identified as CRC risk factors (p < 0.05). The CC and TC genotypes of the rs8720 were associated with rectal cancer, age over 50 years, moderately differentiated histology, and advanced cancer stage. TG and GG genotypes of the rs12587 variant were a risk factor in the CRC group, in patients with stage I–II, males, and stage III–IV non-chemotherapy response. The TG haplotype is protected against CRC. The combined CCGG genotype was linked to CRC risk. In silico analysis revealed that the rs12587 and rs8720 variants could influence KRAS gene regulation via miRNAs. In conclusion, rs8720 and rs12587 variants of the KRAS gene were associated with CRC risk and could influence KRAS regulation via miRNAs.